The role of cytokines in osteoarthritis pathophysiology

Biorheology

Volumn 39, Issue 1-2, 2002, Pages 237-246

  Fernandes, Julio C ^a   Martel Pelletier, Johanne ^a   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Antiinflammatory cytokines; Cytokine antagonists; OA; Proinflammatory cytokines

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; MATRIX METALLOPROTEINASE; MESSENGER RNA; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 4; SOMATOMEDIN C; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL TYPE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SYNOVIOCYTE; SYNOVIUM;

ANIMALS; CARTILAGE, ARTICULAR; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; GENE THERAPY; HUMANS; INTERLEUKINS; MATRIX METALLOPROTEINASE 3; OSTEOARTHRITIS; RECEPTORS, INTERLEUKIN-1; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036286667     PISSN: 0006355X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (93)

1. Differentiation-inducing factor purified from conditioned medium of mitogen-treated spleen cell cultures stimulates bone resorption
2. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
3. Human tumor necrosis factor. Production, purification, and characterization
4. Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha
5. Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: Distinct targeting in the signaling pathways
6. 2 release and on signaling pathways in human OA synovial fibroblasts
7. Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting enzyme in human osteoarthritis
8. Interleukin-1 receptor antagonist
9. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage
10. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation
11. Reduction of tumor necrosis factor alpha and interleukin-1 beta levels in human synovial tissue by interleukin-4 and glucocorticoid
12. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
13. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor
14. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
15. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
16. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: Evidence of feedback control of TNF action
17. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family
18. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha
19. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase-1 expression
20. Leukaemia inhibitory factor stimulates proteoglycan resorption in porcine articular cartilage
21. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis
22. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
23. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells
24. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10
25. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes
26. Interleukin 13 is a B cell stimulating factor
27. Localisation of interleukin 8 in the synovial membrane, cartilage-pannus junction and chondrocytes in rheumatoid arthritis
28. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo
29. Biologic basis for interleukin-1 in disease
30. Differential regulation of IL-1 production in human monocytes by IFN-gamma and IL-4
31. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes
32. Gene therapy for arthritis
33. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis
34. Role of cytokines in rheumatoid arthritis
35. Synovium as a source as interleukin-6 in vitro: Contribution to local and systemic manifestations of arthritis
36. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-alpha
37. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis, In vivo effects of anti-rheumatic drugs
38. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis
39. 2
40. Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors
41. Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor
42. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-kappa B. TNF alpha is not needed for induction of a biological effect via TNF receptors
43. Pathology of osteoarthritis
44. Soluble tumor necrosis factor receptor: Inhibition of human immunodeficiency virus activation
45. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
46. Interleukin-17 (IL-17) stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages
47. Effect of IL-13 on cytokines, cytokine receptors and inhibitors on human osteoarthritic synovium and synovial fibroblasts
48. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes
49. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8
50. Quantitative determination of IL-1 alpha-induced IL-8 mRNA levels in cultured human keratinocytes, dermal fibroblasts, endothelial cells, and monocytes
51. Purification of interleukin-1 beta converting enzyme, the protease that cleaves the interleukin-1 beta precursor
52. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific
53. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis
54. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor
55. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity
56. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis
57. Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes
58. Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases
59. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function
60. MAPK and NF-B together regulate the IL-17-induced nitric oxide production in human OA chondrocytes: Possible role of transactivating factor MAPKAP-K
61. The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor
62. Synovial inflammation in patients with early osteoarthritis of the knee
63. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells
64. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage
65. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine
66. In vivo suppression of early experimental osteoarthritis by IL-Ra using gene therapy
67. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process
68. The role of tumour necrosis factor (TNF) in arthritis: Studies in transgenic mice
69. Leukemia inhibitory factor: A novel bone-active cytokine
70. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
71. Human synovial fibroblasts coexpress interleukin-1 receptor type I and type II mRNA: The increased level of the interleukin-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor
72. Molecular cloning and expression of a receptor for human tumor necrosis factor
73. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses
74. The monocyte-derived neutrophil activating peptide (NAP/interleukin 8) stimulates human neutrophil arachidonate-5-lipoxygenase, but not the release of cellular arachidonate
75. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown
76. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha
77. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors
78. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation
79. Characterization of the structural requirements and cell type specificity of IL-1 and IL-1 secretion
80. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors
81. A receptor for tumor necrosis factor defines an unusual familx of cellular and viral proteins
82. Specific binding of interleukin-1 (IL-1)- and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I
83. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor
84. The two different receptors for tumor necrosis factor mediate distinct cellular responses
85. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses
86. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8
87. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis
88. Coordinated antiinflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist
89. Induction of cytokine expression by leukemia inhibitory factor
90. Tumour necrosis factor-alpha receptor expression on chondrocytes isolated from human articular cartilage
91. Structure and mechanism of interleukin-1 beta converting enzyme
92. Human IL-17: A novel cytokine derived from T cells
93. Interleukin 8 modulates interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha release from normal human mononuclear cells